CERS Cerus: Book Valuation of Business

Public company logo of cerus.com (CERS)

Cerus Corporation (CERS) maintains a dominant position due to its patent portfolio and stringent regulatory requirements for blood safety. This price chart reflects the current level at 0.07. The business relies on external component suppliers, eliminating dependence on any single vendor. Stable government contracts guarantee the company's resilience to economic fluctuations and ensure an absence of seasonality.

Cerus (CERS) Book Capitalization: for the period 07/04/2022 - 10/29/2026

Cerus - analytical breakdowns and key metrics (CERS)

- current price and projected stock value:
Price Performance Chart Cerus Inc|CERS - Price Target Chart
- company stock capitalization data:
Market Capitalization Cerus Corp.|CERS - Total Company Value
- book value of equity indicators:
Accounting Value per Share Cerus|CERS - Book Capitalization|Market-to-Book Ratio cerus.com|CERS - Company Total Assets
- debt and liquidity data:
Debt to Equity Ratio Cerus Corporation|CERS - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Cerus Corp.|CERS - Company Aggregate Debts|Debt to Book Value Cerus Corp.|CERS - Company Long-Term Debts|Company Short-Term Debts Cerus|Quick Liquidity cerus.com
Fundamental company valuation:Cerus Corporation
Finished products of Cerus Corp

Capital control is critical for Cerus Corporation (CERS) amid the slow implementation of pathogen inactivation systems in Europe. This metric is calculated as the difference between all assets and liabilities, reflecting the actual value of net assets. By analyzing the trend of the company's balance sheet capitalization, an investor assesses the business's internal resilience to clinical trial costs. Growth in this metric confirms financial security; however, purchasing the asset at its peak value creates the risk of overpayment.

Competitor analysis for Cerus Corporation

Accounting Value of Company ISRG (Intuitive Corp)|Danaher Corp. (DHR) - Company Book Value|BDX - Book Valuation of Business|Company Book Value STERIS|Company Net Assets West Pharma (WST)|Book Capitalization BAX|MASI - Total Stockholders' Equity|Book Capitalization STVN (Stevanato Group S.p.A.)|TFX: Accounting Capitalization|Merit Medical - Book Capitalization|Book Valuation of Business Envista Holdings Corporation NVST|ICUI: Book Capitalization|Company Net Assets Sirona Dental Systems|LMAT (LeMaitre Vascular, Inc.) - Book Capitalization|Book Capitalization atricure.com|Company Book Value STAAR Surgical (STAA)|Company Book Value NAGE (Chromadex Corp)|ZimVie Dental - Company Net Assets|Accounting Value of Company ANGO|Alpha Teknova, Inc. - Book Capitalization|Book Valuation of Business monogramorthopedics.com MGRM|sharpstechnology.com (STSS) - Company Book Value|Accounting Capitalization INFU|Company Book Value Utah Medical|KORU Medical Systems Inc. (KRMD) - Book Valuation of Business|Company Net Assets NYXH (Nyxoah S.A.)|Total Net Assets MBOT|Company Book Value Pro-Dex PDEX|Accounting Value of Company ZTEK|ELUT: Company Net Assets|MLSS - Book Capitalization|NEXGEL, Inc. (NXGL) - Company Book Value|Company Net Assets Retractable Technologies, Inc.|HBIO (Harvard Bioscience, Inc.) - Book Capitalization|Total Stockholders' Equity Femasys Inc FEMY|Company Book Value MeihuaMed (MHUA)|predictive-oncology.com - Accounting Capitalization|Callan JMB - Company Net Assets|Total Net Assets ATRI (atrioncorp.com)|NURO - Company Book Value